<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198585</url>
  </required_header>
  <id_info>
    <org_study_id>Empire HF</org_study_id>
    <secondary_id>2017-001341-27</secondary_id>
    <nct_id>NCT03198585</nct_id>
  </id_info>
  <brief_title>Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction</brief_title>
  <acronym>Empire HF</acronym>
  <official_title>Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morten Schou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev and Gentofte Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and&#xD;
      during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and&#xD;
      health-related quality of life in stable, symptomatic heart failure patients with reduced&#xD;
      left ventricular ejection fraction.&#xD;
&#xD;
      The primary hypothesis is that 3 months' treatment with Empagliflozin 10 mg a day will reduce&#xD;
      the plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Actual">January 17, 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Between-group difference in the change of plasma concentrations of NT-proBNP</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change in daily activity level measured by patient-worn accelerometers as change in the amount of daily average accelerometer units</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change in body composition assessed by DXA scan</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of estimated extracellular volume assessed by Cr-51 EDTA clearance</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of estimated plasma volume assessed by hematocrit and hemoglobin</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of glucose metabolism assessed by oral glucose tolerance test</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of ketone supply to the heart assessed by blood ketones</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of renal function assessed by Cr-51 EDTA clearance</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of uric acid</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of urine albumin/creatinine ratio</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of cardiac biomarkers assessed by plasma concentrations of MR-proADM and hs-cTnI</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of cardiac systolic and diastolic function including left ventricular global longitudinal strain and left ventricular ejection fraction assessed by transthoracic echocardiography at rest and during stress</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of cardiac hemodynamics during rest and sub-maximal exercise assessed by right heart catheterization including pulmonary capillary wedge pressure to cardiac index ratio</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of cardiac hemodynamics during rest and sub-maximal exercise assessed by right heart catheterization including left ventricular contractile reserve</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of health-related quality of life assessed by the questionnaire KCCQ</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in the change of health-related quality of life assessed by the questionnaire EQ-5D-5L</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Empagliflozin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>Capsule, once a day for 90 days</description>
    <arm_group_label>Empagliflozin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, once a day for 90 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Optimal Heart Failure Therapy in accordance with European and National Guidelines&#xD;
&#xD;
          -  LVEF â‰¤ 0.40&#xD;
&#xD;
          -  eGFR &gt; 30 ml/min/1.73 m2&#xD;
&#xD;
          -  BMI &lt; 45 kg/m2&#xD;
&#xD;
          -  NYHA class I-III&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  If T2D - optimal treatment in accordance with European and National Guidelines&#xD;
&#xD;
          -  If T2D - stable doses of antiglycemic treatment for 30 days&#xD;
&#xD;
          -  If T2D - HbA1C 6.5-10%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CRT-D/-P implanted &lt; 90 days&#xD;
&#xD;
          -  Uncorrected severe valvular disease&#xD;
&#xD;
          -  Non-compliance&#xD;
&#xD;
          -  Use of metalozone&#xD;
&#xD;
          -  NYHA IV&#xD;
&#xD;
          -  Age &gt; 85 years&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Admission for HF &lt; 30 days&#xD;
&#xD;
          -  Admission for hypoglycemia &lt; 12 month&#xD;
&#xD;
          -  Known sustained VT&#xD;
&#xD;
          -  Symptomatic hypotension and systolic BP &lt; 95 mmHg&#xD;
&#xD;
          -  Unable to perform an exercise test&#xD;
&#xD;
          -  Immobilization&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Participation in other medical trials&#xD;
&#xD;
          -  Previous intolerance of Empagliflozin or excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Schou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev and Gentofte University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob E Moller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev and Gentofte University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev and Gentofte Hospital</investigator_affiliation>
    <investigator_full_name>Morten Schou</investigator_full_name>
    <investigator_title>MD, PhD, Consultant Cardiologist, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

